Document is current
Any future updates will be listed below
-
Authors
Assaf, Zoe June F.
Zou, Wei https://orcid.org/0000-0002-3639-9821
Fine, Alexander D.
Socinski, Mark A.
Young, Amanda https://orcid.org/0000-0002-2199-1873
Lipson, Doron
Freidin, Jonathan F. https://orcid.org/0000-0003-1821-8932
Kennedy, Mark
Polisecki, Eliana
Nishio, Makoto
Fabrizio, David
Oxnard, Geoffrey R.
Cummings, Craig
Rode, Anja
Reck, Martin
Patil, Namrata S.
Lee, Mark
Shames, David S. https://orcid.org/0000-0002-5900-1177
Schulze, Katja https://orcid.org/0000-0003-3704-5651
-
Funding
Funding for this research was provided by:
Roche
- License Information
-
More Information
Article History
Received: 29 June 2022
Accepted: 23 January 2023
First Online: 16 March 2023
Competing interests
: Z.J.A., D.S., K.S., C.C., Z.J.A., A.R., M.L., N.P., and W.Z. disclose current or recent employment with Roche. Z.J.A., D.S., K.S., G.O., C.C., M.L., D.F., N.P., W.Z., A.F., D.L., A.R., A.Y., and J.F. disclose stock or other ownership interests with Roche. G.O., A.Y., A.F., D.F., D.L., M.K., E.P., and J.F. disclose current or recent employment with FMI. M.R. discloses funding from Genentech, Pfizer, Spectrum, Takeda, Daiichi Sankyo, AstraZeneca, and Speaker Bureau for Genentech, AstraZeneca, Guardant, Jazz, Janssen and GI Therapeutics. M.S. discloses funding from Genentech, Pfizer, Spectrum, Takeda, Novartis, Beigene, AstraZeneca, and Daiichi Sankyo and discloses speaking fees from Genentech, Lilly, Blueprint, Guardant, BMS, Jazz, GI Therapeutics, Janssen and Amgen. M.L. discloses board member and shareholder in Foresight Diagnostics, scientific advisory board member and shareholder in Delfi Diagnostics and Prognomiq, Inc. The other authors declare no competing interests.
